geht hier was

die Daumen das du deinen Raketenstart ab Montag genießen kannst und
allen Anderen natürlich auch . Anbei noch die Ankündigung von Acer ein
neues Medikament erproben zu wollen ! Es tut sich gewaltiges im Hintergrund !!

https://ownsnap.com/...f-stock-is-on-the-verge-of-breakout-what-next/  

https://lastfuturist.com/...-covid-19-treatments-like-rlftfs-zyesami/



https://informaconnect.com/tides/speakers/jonathan-javitt/  

https://lastfuturist.com/relief-therapeutics-rlftf-2022-prospects/  

https://nocamels.com/2021/05/...harmaceutical-spac-neurorx-valuation/  

Wow, das war ein grüner Montag :-)  

https://www.linkedin.com/posts/...l-activity-6803979985141948417-Kvid  

https://www.prnewswire.com/news-releases/...-respirato-301302408.html  

an FDA war ja bekannt und wurde auch eingehalten. Die beste Nachricht jedoch ist heute, dass Relief Therapeutics alle Daten von ihrem US Partner erhalten haben und somit in Europa loslegen können. Das Sommermärchen kann beginnen

Go go go  

PRESS RELEASE1ReliefTherapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug AdministrationGeneva,  Switzerland, June 2,  2021–RELIEF  THERAPEUTICS  Holding  AG  (SIX:  RLF,  OTCQB:  RLFTF)(“Relief”),  a  biopharmaceutical  company  with  its  lead  compound  RLF-100™ (aviptadil) in advanced clinical development to treat COVID-19-induced respiratory disorders, reported today that its collaboration partner,NRx  Pharmaceuticals,  Inc.  (formerly  known  as:  NeuroRx  Pharmaceuticals,  Inc.), has announced  that  it  has submitted   an   application to   the   U.S.   Food   and   Drug   Administration   (FDA)   seekingEmergency   Use Authorization(EUA)forthe use ofaviptadil in the treatment of critical COVID-19 in patients with respiratory failure.NRx’s press release announcing its EUA submission can be accessed through the following link.  “We are delighted that our partner  has  submitted aviptadil forEUAand  look  forward  to  a  decision  by  the Agency,” said Raghuram  (Ram)  Selvaraju,  Chairman  of  the  Board  of  Relief. “Despite the  increase  in  the number  of  people  being  fully  vaccinated  against  COVID-19, with  emerging  variants and  disparities  in vaccination  rates, there  remains  a  major  need  for effective therapeutic  optionsfor  patients  with  respiratory failure. We are excited about the potential aviptadil holds in helping critical COVID-19 patients and are hopeful that the drug candidate will soon be available to those who remain inneedof bettertreatments.”Dr. Selvaraju continued: “We would also like to take this opportunity to not only congratulate our partner on completing theEUAsubmission but also on their recent listing on Nasdaq.”The EUA  submission  is  based  on  the results  of  a COVID-19 IVrandomized,  placebo-controlled  phase  2b/3clinical trialconducted by NRx in the United States. Relief also confirms that it has received a copy of the clinical study report from this trial from NRx and looks forward topursuingthe best path forward for the development ofIV RLF-100 in Europeand other territories.FDA’s guidance to industry identifies the criteria for EUA as safe and “may be effective,” in contrast to the far more stringent requirement of “safe and effective” required for traditional drug approval. EUA may only be granted  in  circumstances  where  the  Secretary  of  Health  and  Human  Services  has  declared  a  Public  Health Emergency, as is trueforthe COVID-19 pandemic.There is no guidance or  regulation regarding how  quickly FDA will review EUA applications.###
PRESS RELEASE2ABOUT RELIEFRelief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate RLF-100TM(aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical developmentin the U.S. for the treatment of respiratory deficiency due to COVID-19. As  part  of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.  RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visitwww.relieftherapeutics.com.Follow us on LinkedIn.CONTACT:RELIEF THERAPEUTICS Holding AGJack WeinsteinChief Financial Officer and Treasurer Mail: contact@relieftherapeutics.comFOR MEDIA/INVESTOR INQUIRIES: MC Services AGAnne HenneckeTel.: +49 (0) 211-529-252-22Mail:relief@mc-services.euDisclaimer:This   communication   expressly   or   implicitly   contains   certain   forward-looking   statements concerning RELIEF THERAPEUTICS Holding AG, and there can be no assurance that NRx's application for EUA will be approved by the FDA or that Relief will be successful in obtaining approval for the product in Europe or other territories. Such statements involve certain known and unknown risks, uncertainties and other factors, which   could   cause   the   actual   results,   financial   condition,   performance   or   achievements   of   RELIEF THERAPEUTICS Holding AG to be materially different  from any future results, performance or achievements expressed  or  implied  by  such  forward-looking  statements.  RELIEF  THERAPEUTICS  Holding  AG  is  providing this communication as of this date and do not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
 

was ihr mit eurem Stop/Loss anfangt ! Ich würde das Heute
deaktivieren !! :-) Wünsche euch allen einen grünen Mittwoch ! :-)  

orderbook now (est 0.215), 20 minutes till opening:
Briefkurs (ask) Vol. Brief Zeit
0.224 26'217 (2) 07:40:00
0.223 66'637 (2) 07:00:05
0.222 1'264'000 (6) 07:40:00
0.22 386'092 (12) 08:00:03
0.219 143'576 (5) 07:40:00
0.218 100'000 (1) 05:55:02
0.217 4'500 (1) 05:55:02
0.215 20'000 (1) 06:25:00
0.21 100 (1) 08:17:22
Bestens 50'100 (2) 08:29:36
08:18:37 32'000 (6) Bestens
05:55:02 4'000 (1) 0.22
08:30:25 53'920 (4) 0.215
08:30:04 21'629 (3) 0.214
08:31:49 87'420 (8) 0.21
05:55:02 13'958 (2) 0.204
05:55:02 59'889 (2) 0.202
07:40:02 85'000 (8) 0.20
08:23:13 20'000 (1) 0.199
08:14:53 23'000 (2) 0.195
Zeit Vol. Geld Geldkurs (bid)  

Kann mir jemand sagen warum NRX Pharma (ehem. Big Rock Partners & Neurox) von der Zulassung nicht auch wesentlich profitieren solten? Was meint Ihr, sollte man dort einsteigen? Verdient Relief an dem Verkauf von ZYESAMI in Amerika mit? Oder bleibt dort alles bei NRX. Wie sieht es mit dem Rest der Welt aus? Indien? Wer darf dann wo auf der Welt sein Medikament verkaufen?

 

Der anfallende Gewinn wird Prozentual aufgeteilt . Wer wo was vermarktet scheint erst mal zweitrangig zu sein . Was den Gewinn angeht sehe ich grosse Vorteile seitens Relief . :-)

GENEVA, Switzerland and RADNOR, Pa., Sept. 21, 2020 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF,OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc. today announced the completion of their partnership agreement for the commercialization of RLF-100™(Aviptadil) worldwide. The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis. They have agreed that NeuroRx will lead commercialization in the United States, Canada, and Israel, while Relief will lead commercialization in Europe and the rest of the world. Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel, 85/15 (in favor of Relief) in Europe, and 80/20 (in favor of Relief) in all other territories.  

https://www.precisionvaccinations.com/vaccines/...ovid-19-therapeutic  

Wenn ich nen Post von dir sehe muss ich immer grinsen.

Von welcher Marktkapitalisierung träumst du denn? :-)  

deine Frage kann ich leider nicht beantworten aber solltest du hier
investiert sein grinsen wir zusammen .  

Bin noch Dicke im Minus. Aber ich habe Zeit ....  

dann verfasst man langen TZext und kann ihn aus unerklärlichen Gründen nicht posten, weil Inhalte nicht zugelassen sind. Muss ich jetzt die Satzzeichen ändern oder was ?

Echt zum k...  

Ihr Beitrag enthält Inhalte, die nicht veröffentlicht werden dürfen. Bitte formulieren Sie Ihren Beitrag um.

Muss ich denn jetzt meinen ganzen Text umformulieren, um dann die gleiche Nachricht zu erhalten?

Wenn Onvista nicht will , dass man gute und informative Beiträge verfasst verabschiede ich mich hier wieder. Ich sehe in meinem ganzen Text nicht eine einzige Passage, in der eventuell ein verwerfliches Wort stehen würde.

Ich wünsche euch dennoch alles Gute und vielleicht bis dann  

für diejenigen die es noch nicht kennen. Für mich das beste und informativste Börsenforum, dass ich je gesehen haben. Ich kann euch nur anraten dort mal reinzuschauen.  

https://www.investoren.team/threads/rlf-relief-therapeutics.2/  

https://www.finanznachrichten.de/...gegen-relief-therapeutics-485.htm  

Glaube nicht an Ende von Covid 19!  

https://www.youtube.com/watch?v=MONezF-sIw0  Video Youtube


To open the online version please click here.

Dear Sir or Madam,

We would like to draw your attention to the following press release of RELIEF THERAPEUTICS Holding AG:
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19



Geneva, Switzerland, June 16, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief”), a biopharmaceutical company with its lead compound RLF-100™ (aviptadil) in advanced clinical development to treat COVID-19-induced respiratory disorders, reported today that its collaboration partner, NRx Pharmaceuticals, Inc., (Nasdaq: NRXP) (“NRx”) has announced additional results from the aviptadil U.S. Expanded Access Protocol (EAP). The EAP included 240 patients in the intensive care unit (ICU) with critical COVID-19 respiratory failure requiring either invasive or non-invasive mechanical ventilation, or high flow rate oxygen by nasal cannula, and not eligible for the recently completed phase 2b/3 clinical trial with IV aviptadil.  According to NRx’s press release, these EAP data are being submitted by NRx to the U.S. Food and Drug Administration (FDA) as “real world” evidence in support of the findings from the phase 2b/3 trial.  The related NRx press release can be accessed through the following link.



###

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate RLF-100TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical development in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease.



RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com.



Follow us on LinkedIn.





CONTACT:

RELIEF THERAPEUTICS Holding AG

Jack Weinstein

Chief Financial Officer and Treasurer

Mail: contact@relieftherapeutics.com
                
§
FOR MEDIA/INVESTOR INQUIRIES:

MC Services AG

Anne Hennecke

Tel.: +49 (0) 211-529-252-22

Mail: relief@mc-services.eu



Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, and there can be no assurance that NRx's application for EUA will be approved by the FDA or that Relief will be successful in obtaining approval for the product in Europe or other territories. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and do not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

+++ End of press release +++

Should you have any questions or would like to receive further information, please do not hesitate to contact us.

Best regards,

Laurie Doyle
MC Services AG
phone: +1 347 804 6686
email: relief@mc-services.eu

www.mc-services.eu
MC Services AG

Handelsregister/Commercial Register: Amtsgericht Augsburg HRB 2117
Vorstand/Management Board: Raimund Gabriel, Anne Hennecke
Aufsichtsrat/Supervisory Board: Johannes Gabriel (Vorsitzender/Chairman)
This message may contain confidential and/or privileged information. If you are not the addressee or authorized to receive this for the addressee, you must not use, copy, disclose or take any action based on this message or any information herein. If you have received this message in error, please advise the sender immediately by reply e-mail and delete this message. Thank you for your cooperation.
If you wish to be removed from the RELIEF THERAPEUTICS Holdings AG distribution list, please click here.
In accordance with the new EU General Data Protection Regulation (GDPR), we ask for your consent to continue sending you press releases and other information. If we do not receive any feedback from you, we will continue to send you press releases in the future. You can revoke your consent to receive information and to store data at any time and without giving reasons by e-mail to contact@mc-services.eu.
 

Hallo

Und was sagt es jetzt aus wichtig ist die Zulassung oder.

Viele Grüße  

wir hängen am Tropf der FDA/WHO und gehören leider nicht ( nochnicht :-) )
zur Gilde big Pharma . Nichts desto trotz wird weiter kräftig gewerkelt im
Hintergrund und auch in Europa . Hier mal was Interressantes von Advita !! :-)

https://advita-lifescience.com/newsroom/

Die COVID-19-Fallzahlen sinken weiter aber ein Ende der Pandemie ist nicht absehbar. Von verschiedenen Klinikern in Europa wurde der Wunsch geäußert, an der COVID-19-Studie mit inhalativem Aviptadil unter Leitung von Prof. Leuppi teilzunehmen. Die dafür notwendige EudraCT-Nr. wurde uns gestern mitgeteilt. Dadurch kann jedes Krankenhaus innerhalb der EU teilnehmen.